1
|
Thakur V, Thakur V, Aguila B, Slepak T, Wang M, Song W, Konai M, Mobashery S, Chang M, Rana AB, Wang D, de Freitas JT, Gultekin SH, Welford SM, Ivan ME, Bedogni B. Targeting extracellular matrix remodeling sensitizes glioblastoma to ionizing radiation. Neurooncol Adv 2022; 4:vdac147. [PMID: 36212741 PMCID: PMC9536293 DOI: 10.1093/noajnl/vdac147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background The median survival of Glioblastoma multiforme (GBM) patients is 14+ months due to poor responses to surgery and chemoradiation. Means to counteract radiation resistance are therefore highly desirable. We demonstrate the membrane bound matrix metalloproteinase MT1-MMP promotes resistance of GBM to radiation, and that using a selective and brain permeable MT1-MMP inhibitor, (R)-ND336, improved tumor control can be achieved in preclinical studies. Methods Public microarray and RNA-sequencing data were used to determine MT1-MMP relevance in GBM patient survival. Glioma stem-like neurospheres (GSCs) were used for both in vitro and in vivo assays. An affinity resin coupled with proteomics was used to quantify active MT1-MMP in brain tissue of GBM patients. Short hairpin RNA (shRNA)-mediated knockdown of MT1-MMP and inhibition via the MT1-MMP inhibitor (R)-ND336, were used to assess the role of MT1-MMP in radio-resistance. Results MT1-MMP expression inversely correlated with patient survival. Active MT1-MMP was present in brain tissue of GBM patients but not in normal brain. shRNA- or (R)-ND336-mediated inhibition of MT1-MMP sensitized GSCs to radiation leading to a significant increase in survival of tumor-bearing animals. MT1-MMP depletion reduced invasion via the effector protease MMP2; and increased the cytotoxic response to radiation via induction of replication fork stress and accumulation of double strand breaks (DSBs), making cells more susceptible to genotoxic insult. Conclusions MT1-MMP is pivotal in maintaining replication fork stability. Disruption of MT1-MMP sensitizes cells to radiation and can counteract invasion. (R)-ND336, which efficiently penetrates the brain, is therefore a novel radio-sensitizer in GBM.
Collapse
Affiliation(s)
- Varsha Thakur
- Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine , Miami, Florida
- Sylvester Comprehensive Cancer Center , Miami, Florida
| | - Vijay Thakur
- Department of Radiation Oncology, University of Miami Miller School of Medicine , Miami, Florida
- Sylvester Comprehensive Cancer Center , Miami, Florida
| | - Brittany Aguila
- Department of Radiation Oncology, University of Miami Miller School of Medicine , Miami, Florida
- Sylvester Comprehensive Cancer Center , Miami, Florida
| | - Tatiana Slepak
- Department of Neurological Surgery, University of Miami Miller School of Medicine , Miami, Florida
| | - Man Wang
- Department of Chemistry and Biochemistry, University of Notre Dame , Notre Dame, Indiana
| | - Wei Song
- Department of Chemistry and Biochemistry, University of Notre Dame , Notre Dame, Indiana
| | - Mohini Konai
- Department of Chemistry and Biochemistry, University of Notre Dame , Notre Dame, Indiana
| | - Shahriar Mobashery
- Department of Chemistry and Biochemistry, University of Notre Dame , Notre Dame, Indiana
| | - Mayland Chang
- Department of Chemistry and Biochemistry, University of Notre Dame , Notre Dame, Indiana
| | - Ayush B Rana
- Department of Radiation Oncology, University of Miami Miller School of Medicine , Miami, Florida
- Sylvester Comprehensive Cancer Center , Miami, Florida
| | - Dazhi Wang
- Department of Radiation Oncology, University of Miami Miller School of Medicine , Miami, Florida
- Sylvester Comprehensive Cancer Center , Miami, Florida
| | - Juliano Tiburcio de Freitas
- Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine , Miami, Florida
- Sylvester Comprehensive Cancer Center , Miami, Florida
| | - Sakir Humayun Gultekin
- Neuropathology, Division of Anatomic Pathology, University of Miami Miller School of Medicine , Miami, Florida
| | - Scott M Welford
- Department of Radiation Oncology, University of Miami Miller School of Medicine , Miami, Florida
- Sylvester Comprehensive Cancer Center , Miami, Florida
| | - Michael E Ivan
- Department of Neurological Surgery, University of Miami Miller School of Medicine , Miami, Florida
| | - Barbara Bedogni
- Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine , Miami, Florida
- Sylvester Comprehensive Cancer Center , Miami, Florida
| |
Collapse
|
2
|
Aguila B, Morris AB, Spina R, Bar E, Schraner J, Vinkler R, Sohn JW, Welford SM. The Ig superfamily protein PTGFRN coordinates survival signaling in glioblastoma multiforme. Cancer Lett 2019; 462:33-42. [PMID: 31377205 DOI: 10.1016/j.canlet.2019.07.018] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2019] [Revised: 07/23/2019] [Accepted: 07/27/2019] [Indexed: 01/20/2023]
Abstract
Glioblastoma multiforme (GBM) is the most malignant primary brain tumor with a median survival of approximately 14 months. Despite aggressive treatment of surgical resection, chemotherapy and radiation therapy, only 3-5% of GBM patients survive more than 3 years. Contributing to this poor therapeutic response, it is believed that GBM contains both intrinsic and acquired mechanisms of resistance, including resistance to radiation therapy. In order to define novel mediators of radiation resistance, we conducted a functional knockdown screen, and identified the immunoglobulin superfamily protein, PTGFRN. In GBM, PTGFRN is found to be overexpressed and to correlate with poor survival. Reducing PTGFRN expression radiosensitizes GBM cells and potently decreases the rate of cell proliferation and tumor growth. Further, PTGFRN inhibition results in significant reduction of PI3K p110β and phosphorylated AKT, due to instability of p110β. Additionally, PTGFRN inhibition decreases nuclear p110β leading to decreased DNA damage sensing and DNA damage repair. Therefore overexpression of PTGFRN in glioblastoma promotes AKT-driven survival signaling and tumor growth, as well as increased DNA repair signaling. These findings suggest PTGFRN is a potential signaling hub for aggressiveness in GBM.
Collapse
Affiliation(s)
- Brittany Aguila
- Department of Biochemistry, Case Western Reserve University, Cleveland, OH, 44106, USA
| | - Adina Brett Morris
- Department of Pharmacology, Case Western Reserve University, Cleveland, OH, 44106, USA
| | - Raffaella Spina
- Department of Neurological Surgery, Case Western Reserve University, Cleveland, OH, 44106, USA
| | - Eli Bar
- Department of Neurological Surgery, Case Western Reserve University, Cleveland, OH, 44106, USA
| | - Julie Schraner
- Department of Radiation Onoclogy, University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland, OH, 44106, USA
| | - Robert Vinkler
- Department of Radiation Onoclogy, University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland, OH, 44106, USA
| | - Jason W Sohn
- Department of Radiation Oncology, Allegheny Health Network, Pittsburgh, PA, 15212, USA
| | - Scott M Welford
- Department of Radiation Oncology, Miller School of Medicine, University of Miami, Miami, FL, 33136, USA; Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, 33136, USA.
| |
Collapse
|
3
|
Duan W, Gao L, Kalvala A, Aguila B, Brooks C, Mo X, Ding H, Shilo K, Otterson GA, Villalona-Calero MA. Type of TP53 mutation influences oncogenic potential and spectrum of associated K-ras mutations in lung-specific transgenic mice. Int J Cancer 2019; 145:2418-2426. [PMID: 30873587 DOI: 10.1002/ijc.32279] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2018] [Revised: 01/30/2019] [Accepted: 02/28/2019] [Indexed: 11/11/2022]
Abstract
TP53 and K-ras mutations are two of the major genetic alterations in human nonsmall cell lung cancers. The association between these two genes during lung tumorigenesis is unknown. We evaluated the potential of two common Type I (273H, contact) and Type II (175H, conformational) TP53 mutations to induce lung tumors in transgenic mice, as well as K-ras status, and other driver mutations in these tumors. Among 516 (138 nontransgenic, 207 SPC-TP53-273H, 171 SPC-TP53-175H) mice analyzed, 91 tumors, all adenocarcinomas, were observed. Type II mutants developed tumors more frequently (as compared to nontransgenics, p = 0.0003; and Type I, p = 0.010), and had an earlier tumor onset compared to Type I (p = 0.012). K-ras mutations occurred in 21 of 50 (42%) of murine lung tumors sequenced. For both the nontransgenic and the SPC-TP53-273H transgenics, tumor K-ras codon 12-13 mutations occurred after 13 months with a peak incidence at 16-18 months. However, for the SPC-TP53-175H transgenics, K-ras codon 12-13 mutations were observed as early as 6 months, with a peak incidence between the ages of 10-12 months. Codons 12-13 transversion mutations were the predominant changes in the SPC-TP53-175H transgenics, whereas codon 61 transition mutations were more common in the SPC-TP53-273H transgenics. The observation of accelerated tumor onset, early appearance and high frequency of K-ras codon 12-13 mutations in the Type II TP53-175H mice suggests an enhanced oncogenic function of conformational TP53 mutations, and gains in early genetic instability for tumors containing these mutations compared to contact mutations.
Collapse
Affiliation(s)
- Wenrui Duan
- Department of Human & Molecular Genetics, Herbert Wertheim College of Medicine, The Florida International University, Miami, FL, USA.,Biomolecular Sciences Institute, the Florida International University, Miami, FL, USA.,Comprehensive Cancer Center at the Ohio State University College of Medicine and Public Health, Columbus, OH, USA
| | - Li Gao
- Department of Human & Molecular Genetics, Herbert Wertheim College of Medicine, The Florida International University, Miami, FL, USA.,Comprehensive Cancer Center at the Ohio State University College of Medicine and Public Health, Columbus, OH, USA
| | - Arjun Kalvala
- Comprehensive Cancer Center at the Ohio State University College of Medicine and Public Health, Columbus, OH, USA
| | - Brittany Aguila
- Comprehensive Cancer Center at the Ohio State University College of Medicine and Public Health, Columbus, OH, USA
| | - Christopher Brooks
- Comprehensive Cancer Center at the Ohio State University College of Medicine and Public Health, Columbus, OH, USA
| | - Xiaokui Mo
- Comprehensive Cancer Center at the Ohio State University College of Medicine and Public Health, Columbus, OH, USA
| | - Haiming Ding
- Comprehensive Cancer Center at the Ohio State University College of Medicine and Public Health, Columbus, OH, USA
| | - Konstantin Shilo
- Comprehensive Cancer Center at the Ohio State University College of Medicine and Public Health, Columbus, OH, USA
| | - Gregory A Otterson
- Comprehensive Cancer Center at the Ohio State University College of Medicine and Public Health, Columbus, OH, USA
| | - Miguel A Villalona-Calero
- Department of Human & Molecular Genetics, Herbert Wertheim College of Medicine, The Florida International University, Miami, FL, USA.,Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA
| |
Collapse
|
4
|
Thakur V, Zhang K, Savadelis A, Zmina P, Aguila B, Welford SM, Abdul-Karim F, Bonk KW, Keri RA, Bedogni B. The membrane tethered matrix metalloproteinase MT1-MMP triggers an outside-in DNA damage response that impacts chemo- and radiotherapy responses of breast cancer. Cancer Lett 2018; 443:115-124. [PMID: 30502358 DOI: 10.1016/j.canlet.2018.11.031] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2018] [Revised: 11/07/2018] [Accepted: 11/09/2018] [Indexed: 01/18/2023]
Abstract
Breast cancer is the second leading cause of death among women in the US. Targeted therapies exist, however resistance is common and patients resort to chemotherapy. Chemotherapy is also a main treatment for triple negative breast cancer (TNBC) patients; while radiation is delivered to patients with advanced disease to counteract metastasis. Yet, resistance to both chemo- and radiotherapy is still frequent, highlighting a need to provide novel sensitizers. We discovered that MT1-MMP modulates DNA damage responses (DDR) in breast cancer. MT1-MMP expression inversely correlates to chemotherapy response of breast cancer patients. Inhibition of MT1-MMP sensitizes TNBC cells to IR and doxorubicin in vitro, and in vivo in an orthotopic breast cancer model. Specifically, depletion of MT1-MMP causes stalling of replication forks and Double Strand Breaks (DBSs), leading to increased sensitivity to additional genotoxic stresses. These effects are mediated by integrinβ1, as a constitutive active integrinβ1 reverts replication defects and protects cells depleted of MT1-MMP from IR and chemotherapy. These data highlight a novel DNA damage response triggered by MT1-MMP-integrinβ1 and provide a new point of therapeutic targeting that may improve breast cancer patient outcomes.
Collapse
Affiliation(s)
- Varsha Thakur
- Department of Biochemistry, Case Western Reserve University, Cleveland, OH, 44106, USA; Department of Dermatology, University of Miami Miller School of Medicine, Miami, FL, 33136, USA
| | - Keman Zhang
- Department of Biochemistry, Case Western Reserve University, Cleveland, OH, 44106, USA
| | - Alyssa Savadelis
- Department of Biochemistry, Case Western Reserve University, Cleveland, OH, 44106, USA
| | - Patrick Zmina
- Department of Biochemistry, Case Western Reserve University, Cleveland, OH, 44106, USA; Department of Dermatology, University of Miami Miller School of Medicine, Miami, FL, 33136, USA
| | - Brittany Aguila
- Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL, 33136, USA
| | - Scott M Welford
- Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL, 33136, USA
| | - Fadi Abdul-Karim
- Department of Anatomic Pathology, Cleveland Clinic Foundation, Cleveland, OH, 44119, USA
| | - Kristen W Bonk
- Department of Pharmacology, Case Western Reserve University, Cleveland, OH, 44106, USA
| | - Ruth A Keri
- Department of Pharmacology, Case Western Reserve University, Cleveland, OH, 44106, USA
| | - Barbara Bedogni
- Department of Biochemistry, Case Western Reserve University, Cleveland, OH, 44106, USA; Department of Dermatology, University of Miami Miller School of Medicine, Miami, FL, 33136, USA.
| |
Collapse
|
5
|
Duan W, Tang S, Gao L, Dotts K, Fink A, Kalvala A, Aguila B, Villalona-Calero MA. Abstract 1361: Micro RNA-200C is one of the important Fanconi Anemia (FA) pathway downstream regulators in lung cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-1361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The Fanconi Anemia (FA) pathway is essential for human cells to maintain integrity following DNA damage. This pathway is involved in the endogenous repair of double stranded DNA breaks and homologous recombination as well as repair of DNA cross-linking caused by exogenous agents. Cancers with defective FA pathway are expected to be more sensitive to cross-link based therapy, or to treatments in which additional repair mechanisms are targeted. We have recently reported the detection of 22% of NSCLC to be FA functionally inactive by Fanconi Anemia Triple Staining Immunofluorescence (FATSI) test. Studies have shown involvement of certain micro RNA (miRNA) as regulatory elements in the development of lung cancer. We set out to evaluate potential involvement of miRNAs in the regulation of the Fanconi Anemia (FA) pathway. Using Nanostring counter miRNA array we screened 734 different miRNA expression in two FA defective lung cancer cells and matched control cells along with two FA pathway deficient lung tumors and matched non-tumor lung tissue samples. Selected miRNA expression were validated with real-time PCR analysis. miRNA target gene expression was analyzed through AmpliSeq RNA gene expression analysis. Among 734 different miRNAs, a cluster of microRNAs were found to be up-regulated including an important cancer related micro RNA, miR-200C. Nanostring data showed that miR-200C was increased 7.5 fold on average in the FA defective lung cancer cells as compared to control cell. An average of 22 fold increase in miR-200C was detected in the FA defective lung tumor tissues comparing to matching non-tumor tissues. AmpliSeq analysis showed the ZEB1(zinc finger E-box binding homeobox 1) mRNA expression was down regulated in10 out 10 lung tumors (100%) comparing to non-tumor tissues, and 9 out of 10 samples (90%) showed reduction in ZEB2 expression. MiRNA-200C has been reported as a negative regulator of epithelial-mesenchymal transition (EMT) and inhibiting cell migration and invasion by promoting the upregulation of E-cadherin through targeting ZEB1 and ZEB2 transcription factors. Our findings indicate that the FA pathway regulates downstream genes through regulation of miRNAs in lung cancer. MiR-200C appears to be one of the most important FA downstream regulators in lung cancer. Validation with a larger sample size will be needed to confirm our findings.
Citation Format: Wenrui Duan, Shirley Tang, Li Gao, Kathleen Dotts, Andrew Fink, Arjun Kalvala, Brittany Aguila, Miguel A. Villalona-Calero. Micro RNA-200C is one of the important Fanconi Anemia (FA) pathway downstream regulators in lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1361.
Collapse
Affiliation(s)
- Wenrui Duan
- 1Florida International University, Miami, FL
| | | | - Li Gao
- 1Florida International University, Miami, FL
| | | | | | | | | | | |
Collapse
|
6
|
Patel R, Qing Y, Kennedy L, Yan Y, Pink J, Aguila B, Desai A, Gerson SL, Welford SM. MMR Deficiency Does Not Sensitize or Compromise the Function of Hematopoietic Stem Cells to Low and High LET Radiation. Stem Cells Transl Med 2018; 7:513-520. [PMID: 29656536 PMCID: PMC6052615 DOI: 10.1002/sctm.17-0295] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2017] [Accepted: 03/20/2018] [Indexed: 12/12/2022] Open
Abstract
One of the major health concerns on long-duration space missions will be radiation exposure to the astronauts. Outside the earth's magnetosphere, astronauts will be exposed to galactic cosmic rays (GCR) and solar particle events that are principally composed of protons and He, Ca, O, Ne, Si, Ca, and Fe nuclei. Protons are by far the most common species, but the higher atomic number particles are thought to be more damaging to biological systems. Evaluation and amelioration of risks from GCR exposure will be important for deep space travel. The hematopoietic system is one of the most radiation-sensitive organ systems, and is highly dependent on functional DNA repair pathways for survival. Recent results from our group have demonstrated an acquired deficiency in mismatch repair (MMR) in human hematopoietic stem cells (HSCs) with age due to functional loss of the MLH1 protein, suggesting an additional risk to astronauts who may have significant numbers of MMR deficient HSCs at the time of space travel. In the present study, we investigated the effects gamma radiation, proton radiation, and 56 Fe radiation on HSC function in Mlh1+/+ and Mlh1-/- marrow from mice in a variety of assays and have determined that while cosmic radiation is a major risk to the hematopoietic system, there is no dependence on MMR capacity. Stem Cells Translational Medicine 2018;7:513-520.
Collapse
Affiliation(s)
| | - Yulan Qing
- Case Comprehensive Cancer Center, National Center for Regenerative Medicine, Seidman Cancer Center, University Hospitals Cleveland Medical center and Case Western Reserve University, Cleveland, Ohio, USA
| | - Lucy Kennedy
- Unit for Laboratory and Animal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Yan Yan
- Case Comprehensive Cancer Center, National Center for Regenerative Medicine, Seidman Cancer Center, University Hospitals Cleveland Medical center and Case Western Reserve University, Cleveland, Ohio, USA
| | - John Pink
- Case Comprehensive Cancer Center, National Center for Regenerative Medicine, Seidman Cancer Center, University Hospitals Cleveland Medical center and Case Western Reserve University, Cleveland, Ohio, USA
| | - Brittany Aguila
- Department of Biochemistry, Case Western Reserve University, Cleveland, Ohio, USA
| | - Amar Desai
- Case Comprehensive Cancer Center, National Center for Regenerative Medicine, Seidman Cancer Center, University Hospitals Cleveland Medical center and Case Western Reserve University, Cleveland, Ohio, USA
| | - Stanton L Gerson
- Case Comprehensive Cancer Center, National Center for Regenerative Medicine, Seidman Cancer Center, University Hospitals Cleveland Medical center and Case Western Reserve University, Cleveland, Ohio, USA
| | - Scott M Welford
- Department of Radiation Oncology, Sylvester Cancer Center, University of Miami, Miami, Florida, USA
| |
Collapse
|
7
|
Du W, Zhang L, Brett-Morris A, Aguila B, Kerner J, Hoppel CL, Puchowicz M, Serra D, Herrero L, Rini BI, Campbell S, Welford SM. HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism. Nat Commun 2017; 8:1769. [PMID: 29176561 PMCID: PMC5701259 DOI: 10.1038/s41467-017-01965-8] [Citation(s) in RCA: 264] [Impact Index Per Article: 37.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2016] [Accepted: 10/30/2017] [Indexed: 01/17/2023] Open
Abstract
Clear cell renal cell carcinoma (ccRCC) is histologically defined by its lipid and glycogen-rich cytoplasmic deposits. Alterations in the VHL tumor suppressor stabilizing the hypoxia-inducible factors (HIFs) are the most prevalent molecular features of clear cell tumors. The significance of lipid deposition remains undefined. We describe the mechanism of lipid deposition in ccRCC by identifying the rate-limiting component of mitochondrial fatty acid transport, carnitine palmitoyltransferase 1A (CPT1A), as a direct HIF target gene. CPT1A is repressed by HIF1 and HIF2, reducing fatty acid transport into the mitochondria, and forcing fatty acids to lipid droplets for storage. Droplet formation occurs independent of lipid source, but only when CPT1A is repressed. Functionally, repression of CPT1A is critical for tumor formation, as elevated CPT1A expression limits tumor growth. In human tumors, CPT1A expression and activity are decreased versus normal kidney; and poor patient outcome associates with lower expression of CPT1A in tumors in TCGA. Together, our studies identify HIF control of fatty acid metabolism as essential for ccRCC tumorigenesis. Clear cell renal cancers (ccRCC) display elevated intracellular lipid storage. Here the authors show that such lipid accumulation is due to the repression of carnitine palmitoyltransferase 1A (CPT1A) enzyme that impairs fatty acid (FA) transport into the mitochondrion resulting in reduced FA beta oxidation.
Collapse
Affiliation(s)
- Weinan Du
- Department of Radiation Oncology, Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OH, 44106, USA
| | - Luchang Zhang
- Department of Radiation Oncology, Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OH, 44106, USA
| | - Adina Brett-Morris
- Department of Radiation Oncology, Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OH, 44106, USA
| | - Brittany Aguila
- Department of Radiation Oncology, Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OH, 44106, USA
| | - Janos Kerner
- Department of Pharmacology, Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OH, 44106, USA
| | - Charles L Hoppel
- Department of Pharmacology, Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OH, 44106, USA.,Department of Medicine, Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OH, 44106, USA
| | - Michelle Puchowicz
- Department of Nutrition, Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OH, 44106, USA
| | - Dolors Serra
- Department of Biochemistry and Physiology, Institut de Biomedicina de la Universitat de Barcelona (IBUB), Universitat de Barcelona, E-08028, Barcelona, Spain.,Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, E-28029, Madrid, Spain
| | - Laura Herrero
- Department of Biochemistry and Physiology, Institut de Biomedicina de la Universitat de Barcelona (IBUB), Universitat de Barcelona, E-08028, Barcelona, Spain.,Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, E-28029, Madrid, Spain
| | - Brian I Rini
- Department of Hematology and Oncology, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH, 44106, USA
| | - Steven Campbell
- Department of Urology, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH, 44106, USA
| | - Scott M Welford
- Department of Radiation Oncology, Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OH, 44106, USA.
| |
Collapse
|
8
|
Fink A, Kalvala A, Gao L, Dotts K, Aguila B, Tang S, Otterson GA, Villalona-Calero MA, Duan W. Abstract 4438: Promoter hypermethylation status of Fanconi Anemia (FA) pathway genes FANCF, FANCL and FANCS in non-small cell lung cancer (NSCLC). Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-4438] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Gene promoter methylation is an epigenetic mechanism used by cells to control gene expression. Over recent decades, scientists have made various discoveries linking DNA methylation to several adverse outcomes, including human cancers. The Fanconi Anemia (FA) pathway is involved in homologous recombination, one of the major mechanisms of DNA repair. This pathway is essential for human cells to maintain integrity following DNA damage. Cancers with defective FA pathways are expected to be more sensitive to cross-link based therapy, or to treatments in which additional repair mechanisms are targeted. The FA pathway contains at least 19 genes, and some of the members have been implicated in susceptibility to a number of cancers by genetic or epigenetic alterations. Promoter methylation in FA genes is thought to play a role in the occurrence of cancer.
Recently we screened 139 non-small cell lung cancer (NSCLC) formalin-fixed, paraffin-embedded (FFPE) tumors for FANCD2 foci formation by FA triple stain immunofluorescence (FATSI) analysis. Among the 104 evaluable tumors, 23 (22%) were FANCD2 foci negative. Since epigenetic inactivation can be one of the mechanisms for FA functional deficiency in these tumors, we evaluated 39 NSCLC samples (21 foci positive and 18 foci negative; 21 adenocarcinomas, 17 squamous cell carcinomas, 1 large cell carcinoma) for FANCF, FANCL and FANCS (BRCA1) promoter methylation.
Human lung tumor tissue samples were obtained from The Tissue Procurement Shared Resources of the Ohio State University after IRB approval. Genomic DNA and total RNA samples were isolated from frozen lung tumor and matching non-tumor tissues. The promoter methylation status of FANCF, FANCL and FANCS was evaluated using methylation-specific PCR (MS-PCR).
Among the 18 FATSI negative tumors, promoter methylation was found in FANCF (1 adenocarcinoma), FANCL (1 adenocarcinoma) and FANCS (1 adenocarcinoma). Among the 21 FATSI positive tumors, no promoter methylation was detected in FANCF or FANCL. Promoter methylation in FANCS was found in 1 (squamous cell carcinoma) of 21 FATSI positive tumors.
The above observations suggest that epigenetic alterations, specifically methylation, can be one of the factors that contribute to FA functional deficiency in NSCLC patients. These findings may have clinical implications, since these tumors may be more sensitive to cross-link based therapy. However, an important caveat is that these changes may not be stable and could revert during treatment. Further studies in FA gene expression are needed to determine the impact of FA gene promoter methylation on FA repair foci formation.
Citation Format: Andrew Fink, Arjun Kalvala, Li Gao, Kathleen Dotts, Brittany Aguila, Shirley Tang, Gregory A. Otterson, Miguel A. Villalona-Calero, Wenrui Duan. Promoter hypermethylation status of Fanconi Anemia (FA) pathway genes FANCF, FANCL and FANCS in non-small cell lung cancer (NSCLC). [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4438.
Collapse
Affiliation(s)
| | | | - Li Gao
- Ohio State University, Columbus, OH
| | | | | | | | | | | | | |
Collapse
|
9
|
Kalvala A, Gao L, Aguila B, Dotts K, Rahman M, Nana-Sinkam SP, Zhou X, Wang QE, Amann J, Otterson GA, Villalona-Calero MA, Duan W. Rad51C-ATXN7 fusion gene expression in colorectal tumors. Mol Cancer 2016; 15:47. [PMID: 27296891 PMCID: PMC4906819 DOI: 10.1186/s12943-016-0527-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2015] [Accepted: 05/20/2016] [Indexed: 11/10/2022] Open
Abstract
Background Fusion proteins have unique oncogenic properties and their identification can be useful either as diagnostic or therapeutic targets. Next generation sequencing data have previously shown a fusion gene formed between Rad51C and ATXN7 genes in the MCF7 breast cancer cell line. However, the existence of this fusion gene in colorectal patient tumor tissues is largely still unknown. Methods We evaluated for the presence of Rad51C-ATXN7 fusion gene in colorectal tumors and cells by RT-PCR, PCR, Topo TA cloning, Real time PCR, immunoprecipitation and immunoblotting techniques. Results We identified two forms of fusion mRNAs between Rad51C and ATXN7 in the colorectal tumors, including a Variant 1 (fusion transcript between Rad51C exons 1–7 and ATXN7 exons 6–13), and a Variant 2 (between Rad51C exons 1–6 and ATXN7 exons 6–13). In silico analysis showed that the Variant 1 produces a truncated protein, whereas the Variant 2 was predicted to produce a fusion protein with molecular weight of 110 KDa. Immunoprecipitation and Western blot analysis further showed a 110 KDa protein in colorectal tumors. 5-Azacytidine treatment of LS-174 T cells caused a 3.51-fold increase in expression of the fusion gene (Variant 2) as compared to no treatment controls evaluated by real time PCR. Conclusion In conclusion we found a fusion gene between DNA repair gene Rad51C and neuro-cerebral ataxia Ataxin-7 gene in colorectal tumors. The in-frame fusion transcript of Variant 2 results in a fusion protein with molecular weight of 110 KDa. In addition, we found that expression of fusion gene is associated with functional impairment of Fanconi Anemia (FA) DNA repair pathway in colorectal tumors. The expression of Rad51C-ATXN7 in tumors warrants further investigation, as it suggests the potential of the fusion gene in treatment and predictive value in colorectal cancers. Electronic supplementary material The online version of this article (doi:10.1186/s12943-016-0527-1) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Arjun Kalvala
- Comprehensive Cancer Center, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA
| | - Li Gao
- Comprehensive Cancer Center, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA
| | - Brittany Aguila
- Comprehensive Cancer Center, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA
| | - Kathleen Dotts
- Comprehensive Cancer Center, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA
| | - Mohammad Rahman
- Comprehensive Cancer Center, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA
| | - Serge P Nana-Sinkam
- Comprehensive Cancer Center, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA.,Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA
| | - Xiaoping Zhou
- Department of Pathology, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA
| | - Qi-En Wang
- Department of Radiology, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA
| | - Joseph Amann
- Comprehensive Cancer Center, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA.,Division of Medical Oncology Department of Internal Medicine, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA
| | - Gregory A Otterson
- Comprehensive Cancer Center, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA.,Division of Medical Oncology Department of Internal Medicine, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA
| | - Miguel A Villalona-Calero
- Comprehensive Cancer Center, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA. .,Division of Medical Oncology Department of Internal Medicine, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA. .,Department of Pharmacology, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA.
| | - Wenrui Duan
- Comprehensive Cancer Center, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA. .,Division of Medical Oncology Department of Internal Medicine, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA.
| |
Collapse
|
10
|
Kalvala A, Gao L, Aguila B, Reese T, Otterson GA, Villalona-Calero MA, Duan W. Overexpression of Rad51C splice variants in colorectal tumors. Oncotarget 2016; 6:8777-87. [PMID: 25669972 PMCID: PMC4496183 DOI: 10.18632/oncotarget.3209] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2014] [Accepted: 12/24/2014] [Indexed: 01/04/2023] Open
Abstract
Functional alterations in Rad51C are the cause of the Fanconi anemia complementation group O (FANCO) gene disorder. We have identified novel splice variants of Rad51C mRNA in colorectal tumors and cells. The alternatively spliced transcript variants are formed either without exon-7 (variant 1), without exon 6 and 7 (variant 2) or without exon 7 and 8 (variant 3). Real time PCR analysis of nine pair-matched colorectal tumors and non-tumors showed that variant 1 was overexpressed in tumors compared to matched non-tumors. Among 38 colorectal tumor RNA samples analyzed, 18 contained variant 1, 12 contained variant 2, 14 contained variant 3, and eight expressed full length Rad51C exclusively. Bisulfite DNA sequencing showed promoter methylation of Rad51C in tumor cells. 5-azacytidine treatment of LS-174T cells caused a 14 fold increase in variant 1, a 4.8 fold increase for variant 3 and 3.4 fold for variant 2 compared to 2.5 fold increase in WT. Expression of Rad51C variants is associated with FANCD2 foci positive colorectal tumors and is associated with microsatellite stability in those tumors. Further investigation is needed to elucidate differential function of the Rad51C variants to evaluate potential effects in drug resistance and DNA repair.
Collapse
Affiliation(s)
- Arjun Kalvala
- Comprehensive Cancer Center, The Ohio State University College of Medicine and Public Health, Columbus, Ohio, U.S.A
| | - Li Gao
- Comprehensive Cancer Center, The Ohio State University College of Medicine and Public Health, Columbus, Ohio, U.S.A
| | - Brittany Aguila
- Comprehensive Cancer Center, The Ohio State University College of Medicine and Public Health, Columbus, Ohio, U.S.A
| | - Tyler Reese
- Comprehensive Cancer Center, The Ohio State University College of Medicine and Public Health, Columbus, Ohio, U.S.A
| | - Gregory A Otterson
- Comprehensive Cancer Center, The Ohio State University College of Medicine and Public Health, Columbus, Ohio, U.S.A.,Division of Medical Oncology Department of Internal Medicine, The Ohio State University College of Medicine and Public Health, Columbus, Ohio, U.S.A
| | - Miguel A Villalona-Calero
- Comprehensive Cancer Center, The Ohio State University College of Medicine and Public Health, Columbus, Ohio, U.S.A.,Division of Medical Oncology Department of Internal Medicine, The Ohio State University College of Medicine and Public Health, Columbus, Ohio, U.S.A.,Department of Pharmacology at The Ohio State University College of Medicine and Public Health, Columbus, Ohio, U.S.A
| | - Wenrui Duan
- Comprehensive Cancer Center, The Ohio State University College of Medicine and Public Health, Columbus, Ohio, U.S.A.,Division of Medical Oncology Department of Internal Medicine, The Ohio State University College of Medicine and Public Health, Columbus, Ohio, U.S.A
| |
Collapse
|
11
|
Gao L, Duan W, Dotts K, Kalvala A, Aguila B, Otterson GA, Villalona-Calero MA. Abstract 559: Inhibition of pro-survival pathways in lung cancer cells with functional defects in the Fanconi Anemia pathway. Cancer Res 2015. [DOI: 10.1158/1538-7445.am2015-559] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
There is a growing appreciation that defects in homologous recombination repair may increase sensitivity of tumors to certain DNA-damaging agents, plausibly through a synthetic lethal interaction. The Fanconi Anemia (FA) pathway is a major mechanism of homologous recombination (HR) DNA repair. Deficiencies in FA pathway have been reported as a predictor of cisplatin, mitomycin C (MMC) or PARP inhibitor sensitivity in cancer cells. The novel PARP inhibitor BMN-673 has emerged from preclinical studies as a best in class PARP trapping agent. BMN-673 has also demonstrated single-agent cytotoxicity in BRCA mutant cells, and activity in cancer patients with BRCA germ line deficiency.
To evaluate novel targeted agents in the background of FA deficiency we utilized RNAi technology to generate several lung cancer cell lines with FANCD2 deficiency. Successful FANCD2 knockdown was confirmed by reduction in the FANCD2 protein. Cell viability was evaluated with MTT assay.
We treated the FA defective H1299D2-down and A549D2-down non-small cell lung cancer cells and their FA competent counterparts H1299E and A549E (empty vector controls) with the PARP inhibitors veliparib (ABT-888, 5μM) and BMN673 (0.5μM), as well as with the CHK1 inhibitor Arry-575 at a dose of 0.5μM. We also treated the BCL2 expressing small cell lung cancer cells H719D2-down, H792D2-down and their controls H719E and H792E with the BCL2/XL inhibitor navitoclax (ABT263) at a dose of 2μM. The treated cells were harvested at 24, 48 and 72 hours (h) post treatment.
Cell viability analysis showed that H1299D2-down cells had 80% of viable cells compared to 100% viable cells in H1299E controls 72h post treatment with veliparib. The A549D2-down cells had 68% viable cells compared to 83% viable cells in the A549E cells 72 h post veliparib treatment. FA defective cells were also more sensitive to treatment of BMN-673 (25% for H1299D2-down vs 62% for H1299E; 29% for A549D2-down vs 46% for A549E) 72 h post BMN-673 treatment at dose of 0.5μM. BMN-673 was more potent compared to veliparib.
FA defective cells were also more sensitive to the treatment of CHK1 or BCL2/XL inhibition. H1299D2-down cells had 38% of viable cells comparing to 60% viable cells in the H1299E cells post treatment of CHK1 inhibitor Arry-575 at a dose of 0.5 μM. In addition, MTT analysis showed that BCL2/XL inhibitor navitoclax was more cytotoxic to the H719D2-down (51%) as compared to H719E (85%) 48 h post treatment. Similarly, the H792D2-down cells were more sensitive to the treatment of navitoclax (58% viable cell) as compared to H792E cells (86% viable cell) 48 h post treatment at dose of 2μM.
Given that FA pathway plays essential roles in response to DNA damage, our results suggest that a subset of lung cancer patients are likely to be more susceptible to treatments in which additional pathways (e.g PARP, CHK1 and BCL2/XL) are targeted. Clinical trials to evaluate this therapeutic concept are needed.
Citation Format: Li Gao, Wenrui Duan, Kathleen Dotts, Arjun Kalvala, Brittany Aguila, Gregory A. Otterson, Miguel A. Villalona-Calero. Inhibition of pro-survival pathways in lung cancer cells with functional defects in the Fanconi Anemia pathway. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 559. doi:10.1158/1538-7445.AM2015-559
Collapse
Affiliation(s)
- Li Gao
- Ohio State University, Columbus, OH
| | | | | | | | | | | | | |
Collapse
|
12
|
Duan W, Gao L, Aguila B, Kalvala A, Otterson GA, Villalona-Calero MA. Fanconi anemia repair pathway dysfunction, a potential therapeutic target in lung cancer. Front Oncol 2014; 4:368. [PMID: 25566506 PMCID: PMC4271581 DOI: 10.3389/fonc.2014.00368] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2014] [Accepted: 12/04/2014] [Indexed: 12/15/2022] Open
Abstract
The Fanconi anemia (FA) pathway is a major mechanism of homologous recombination DNA repair. The functional readout of the pathway is activation through mono-ubiquitination of FANCD2 leading to nuclear foci of repair. We have recently developed an FA triple-staining immunofluorescence based method (FATSI) to evaluate FANCD2 foci formation in formalin fixed paraffin-embedded (FFPE) tumor samples. DNA-repair deficiencies have been considered of interest in lung cancer prevention, given the persistence of damage produced by cigarette smoke in this setting, as well as in treatment, given potential increased efficacy of DNA-damaging drugs. We screened 139 non-small cell lung cancer (NSCLC) FFPE tumors for FANCD2 foci formation by FATSI analysis. Among 104 evaluable tumors, 23 (22%) were FANCD2 foci negative, thus repair deficient. To evaluate and compare novel-targeted agents in the background of FA deficiency, we utilized RNAi technology to render several lung cancer cell lines FANCD2 deficient. Successful FANCD2 knockdown was confirmed by reduction in the FANCD2 protein. Subsequently, we treated the FA defective H1299D2-down and A549D2-down NSCLC cells and their FA competent counterparts (empty vector controls) with the PARP inhibitors veliparib (ABT-888) (5 μM) and BMN673 (0.5 μM), as well as the CHK1 inhibitor Arry-575 at a dose of 0.5 μM. We also treated the FA defective small cell lung cancer cell lines H719D2-down and H792D2-down and their controls with the BCL-2/XL inhibitor ABT-263 at a dose of 2 μM. The treated cells were harvested at 24, 48, and 72 h post treatment. MTT cell viability analysis showed that each agent was more cytotoxic to the FANCD2 knock-down cells. In all tests, the FA defective lung cancer cells had less viable cells as comparing to controls 72 h post treatment. Both MTT and clonogenic analyses comparing the two PARP inhibitors, showed that BMN673 was more potent compared to veliparib. Given that FA pathway plays essential roles in response to DNA damage, our results suggest that a subset of lung cancer patients are likely to be more susceptible to DNA cross-link based therapy, or to treatments in which additional repair mechanisms are targeted. These subjects can be identified through FATSI analysis. Clinical trials to evaluate this therapeutic concept are needed.
Collapse
Affiliation(s)
- Wenrui Duan
- Comprehensive Cancer Center, The Ohio State University College of Medicine and Public Health , Columbus, OH , USA ; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine and Public Health , Columbus, OH , USA
| | - Li Gao
- Comprehensive Cancer Center, The Ohio State University College of Medicine and Public Health , Columbus, OH , USA
| | - Brittany Aguila
- Comprehensive Cancer Center, The Ohio State University College of Medicine and Public Health , Columbus, OH , USA
| | - Arjun Kalvala
- Comprehensive Cancer Center, The Ohio State University College of Medicine and Public Health , Columbus, OH , USA
| | - Gregory A Otterson
- Comprehensive Cancer Center, The Ohio State University College of Medicine and Public Health , Columbus, OH , USA ; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine and Public Health , Columbus, OH , USA
| | - Miguel A Villalona-Calero
- Comprehensive Cancer Center, The Ohio State University College of Medicine and Public Health , Columbus, OH , USA ; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine and Public Health , Columbus, OH , USA ; Department of Pharmacology, The Ohio State University College of Medicine and Public Health , Columbus, OH , USA
| |
Collapse
|
13
|
Zimmerman B, Beautrait A, Aguila B, Charles R, Escher E, Claing A, Bouvier M, Laporte SA. Differential -Arrestin-Dependent Conformational Signaling and Cellular Responses Revealed by Angiotensin Analogs. Sci Signal 2012; 5:ra33. [DOI: 10.1126/scisignal.2002522] [Citation(s) in RCA: 126] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
|
14
|
Aguila B, Coulbault L, Boulouard M, Léveillé F, Davis A, Tóth G, Borsodi A, Balboni G, Salvadori S, Jauzac P, Allouche S. In vitro
and in vivo
pharmacological profile of UFP-512, a novel selective δ-opioid receptor agonist; correlations between desensitization and tolerance. Br J Pharmacol 2009. [DOI: 10.1038/sj.bjp.0707613] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
15
|
Falero A, Llanes N, Pérez C, Fonseca M, Aguila B, Borrego S, Lightbourne E, González VL. Quantitative RP high-performance liquid chromatography of thymine and thymidine. J Sep Sci 2001. [DOI: 10.1002/1615-9314(20010601)24:6<479::aid-jssc479>3.0.co;2-a] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|